CAPS 37.00 Capstone Therapeutics Corp.
| Range: | 3.2-7.5 | Vol Avg: | 21 | Last Div: | 0 | Changes: | -0.05 |
| Beta: | -0.75 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Jan 28 1993 | Empoloyees: | 46 | ||
| CUSIP: | 14068E208 | CIK: | ISIN: | US14068E2081 | Country: | US | |
| CEO: | Mr. Michael M. Toporek III | Website: | https://www.capstonethx.com | ||||
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow